Drug intelligence / Profile preview

INT-004

Development stage: Unknown
Lead developer: IMMUNEO Therapeutics
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

INT-004 (also known as Pan-BITAP) is a peptide-based cancer vaccine being developed by IMMUNEO Therapeutics for the treatment of pancreatic cancer. It is built upon the company's proprietary **BITAP** (Bispecific Immunotherapy Activating Peptides) platform. The vaccine is designed to present a combination of **tumor-specific antigens (TSA)** and **tumor-associated antigens (TAA)** to the patient's immune system. By targeting these specific markers, INT-004 aims to elicit a potent, tumor-directed T-cell immune response capable of recognizing and eliminating pancreatic cancer cells while minimizing damage to healthy tissue. The drug is currently in early-stage clinical development.

Other names: Pan-BITAP

Targets

pMHC-II (Peptide-major histocompatibility complex class II complex)

Beyond the preview

Go deeper on INT-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INT-004.

Explore the full profile